Skip to main content

Cancer Chemotherapy and Pharmacology

Ausgabe 5/2010

Inhalt (22 Artikel)

Original Article

Extracellular fluid concentrations of cisplatin, carboplatin, and oxaliplatin in brain, muscle, and blood measured using microdialysis in nonhuman primates

Shana Jacobs, Cynthia L. McCully, Robert F. Murphy, John Bacher, Frank M. Balis, Elizabeth Fox

Original Article

Epidermal growth factor receptor (EGFR) mRNA levels and protein expression levels in primary colorectal cancer and corresponding liver metastases

Hidekazu Kuramochi, Kazuhiko Hayashi, Go Nakajima, Hirotaka Kamikozuru, Masakazu Yamamoto, Kathleen D. Danenberg, Peter V. Danenberg

Original Article

A phase I trial of SJG-136 (NSC#694501) in advanced solid tumors

Yelena Y. Janjigian, Wooin Lee, Mark G. Kris, Vincent A. Miller, Lee M. Krug, Christopher G. Azzoli, Emir Senturk, M. Wade Calcutt, Naiyer A. Rizvi

Original Article

Limited inter-occasion variability in relation to inter-individual variability in chemotherapy-induced myelosuppression

Emma K. Hansson, Johan E. Wallin, Henrik Lindman, Marie Sandström, Mats O. Karlsson, Lena E. Friberg

Original Article

A phase I dose escalation study of a pharmacobiologically based scheduling of capecitabine and mitomycin C in patients with gastrointestinal malignancies

Tanios Bekaii-Saab, Marisa Hill, Angela Campbell, Kavitha Kosuri, James Thomas, Miguel Villalona-Calero

Original Article

A phase IB dose-finding trial of liposomal doxorubicin in combination with capecitabine in patients with pretreated metastatic breast cancer

Andrea Rocca, Roberta Maltoni, Alessandro Passardi, Ilaria Massa, Michele Aquilina, Ruggero Ridolfi, Toni Ibrahim, Lorenzo Cecconetto, Samanta Sarti, Elisabetta Pietri, Oriana Nanni, Dino Amadori

Original Article

Induction of necrosis and cell cycle arrest in murine cancer cell lines by Melaleuca alternifolia (tea tree) oil and terpinen-4-ol

S. J. Greay, D. J. Ireland, H. T. Kissick, A. Levy, M. W. Beilharz, T. V. Riley, C. F. Carson

Original Article

Expression of an activated mammalian target of rapamycin (mTOR) in gastroenteropancreatic neuroendocrine tumors

Takashi Shida, Takashi Kishimoto, Mitsuko Furuya, Takashi Nikaido, Keiji Koda, Shigetsugu Takano, Fumio Kimura, Hiroaki Shimizu, Hiroyuki Yoshidome, Masayuki Ohtsuka, Tohru Tanizawa, Yukio Nakatani, Masaru Miyazaki

Original Article

Celecoxib inhibits MDR1 expression through COX-2-dependent mechanism in human hepatocellular carcinoma (HepG2) cell line

Karnati R. Roy, Gorla V. Reddy, Leela Maitreyi, Smita Agarwal, Chandrani Achari, Shireen Vali, Pallu Reddanna

Original Article

Optimization of the non-invasive 13C-sucrose breath test in a rat model of methotrexate-induced mucositis

K. L. Tooley, G. S. Howarth, K. A. Lymn, R. N. Butler

Open Access Original Article

Preclinical efficacy studies of a novel nanoparticle-based formulation of paclitaxel that out-performs Abraxane

Zhongling Feng, Gang Zhao, Lei Yu, David Gough, Stephen B. Howell

Original Article

Antimetastatic, antineoplastic, and toxic effects of 4-hydroxycoumarin in a preclinical mouse melanoma model

Nohemí Salinas-Jazmín, Marisol de la Fuente, Ruth Jaimez, Mayra Pérez-Tapia, Armando Pérez-Torres, Marco A. Velasco-Velázquez

Original Article

Mechanistic study of BNP7787-mediated cisplatin nephroprotection: modulation of gamma-glutamyl transpeptidase

Frederick H. Hausheer, Dakshine Shanmugarajah, Betsy D. Leverett, Xinghai Chen, Quili Huang, Harry Kochat, Pavankumar N. Petluru, Aulma R. Parker

Original Article

Co-administration of irinotecan decreases the plasma concentration of an active metabolite of amrubicin, amrubicinol in rats

Yukiko Maeda, Akinobu Hamada, Emiko Sanematsu, Ji-ichro Sasaki, Koji Yokoo, Asumi Hira, Hideyuki Saito

Open Access Original Article

Phase II study of motesanib in Japanese patients with advanced gastrointestinal stromal tumors with prior exposure to imatinib mesylate

Akira Sawaki, Yasuhide Yamada, Yoshito Komatsu, Tatsuo Kanda, Toshihiko Doi, Masato Koseki, Hideo Baba, Yu-Nien Sun, Koji Murakami, Toshirou Nishida

Original Article

Increased anti-tumour effects of doxorubicin and zoledronic acid in prostate cancer cells in vitro: supporting the benefits of combination therapy

Rhys D. Clyburn, Penny Reid, Catherine A. Evans, Diane V. Lefley, Ingunn Holen

Clinical Trial Report

A phase I/II trial of vorinostat in combination with 5-fluorouracil in patients with metastatic colorectal cancer who previously failed 5-FU-based chemotherapy

Peter M. Wilson, Anthony El-Khoueiry, Syma Iqbal, William Fazzone, Melissa J. LaBonte, Susan Groshen, Dongyun Yang, Kathy D. Danenberg, Sarah Cole, Margaret Kornacki, Robert D. Ladner, Heinz-Josef Lenz

Short Communication

DNA damage induced by the anthracycline cosmomycin D in DNA repair-deficient cells

Helotonio Carvalho, Leandro M. Garrido, Renata L. A. Furlan, Gabriel Padilla, Mateus Agnoletto, Temenouga Guecheva, João A. P. Henriques, Jenifer Saffi, Carlos Frederico Martins Menck

Open Access Short Communication

In vitro assessment of cytochrome P450 inhibition and induction potential of azacitidine

Yong Chen, Lisa Liu, Eric Laille, Gondi Kumar, Sekhar Surapaneni

Labor, CT-Anthropometrie zeigen Risiko für Pankreaskrebs

13.05.2024 Pankreaskarzinom Nachrichten

Gerade bei aggressiven Malignomen wie dem duktalen Adenokarzinom des Pankreas könnte Früherkennung die Therapiechancen verbessern. Noch jedoch klafft hier eine Lücke. Ein Studienteam hat einen Weg gesucht, sie zu schließen.

Viel pflanzliche Nahrung, seltener Prostata-Ca.-Progression

12.05.2024 Prostatakarzinom Nachrichten

Ein hoher Anteil pflanzlicher Nahrung trägt möglicherweise dazu bei, das Progressionsrisiko von Männern mit Prostatakarzinomen zu senken. In einer US-Studie war das Risiko bei ausgeprägter pflanzlicher Ernährung in etwa halbiert.

Alter verschlechtert Prognose bei Endometriumkarzinom

11.05.2024 Endometriumkarzinom Nachrichten

Ein höheres Alter bei der Diagnose eines Endometriumkarzinoms ist mit aggressiveren Tumorcharakteristika assoziiert, scheint aber auch unabhängig von bekannten Risikofaktoren die Prognose der Erkrankung zu verschlimmern.

Darf man die Behandlung eines Neonazis ablehnen?

08.05.2024 Gesellschaft Nachrichten

In einer Leseranfrage in der Zeitschrift Journal of the American Academy of Dermatology möchte ein anonymer Dermatologe bzw. eine anonyme Dermatologin wissen, ob er oder sie einen Patienten behandeln muss, der eine rassistische Tätowierung trägt.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.